Thrombocythemia Myelofibrosis is an indication for drug development with over 40 pipeline drugs currently active. According to GlobalData, preregistered drugs for Thrombocythemia Myelofibrosis have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Thrombocythemia Myelofibrosis compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Thrombocythemia Myelofibrosis overview

Essential thrombocythemia (ET) is a rare blood cancer that causes the body to produce too many platelets. Thrombocythemia is most often caused by gene mutations of JAK2, CALR, and MPL genes that affect formation of platelets from bone marrow. Exposure to benzene may increase the risk of developing myeloproliferative neoplasms. Signs and symptoms may include: Feeling tired, weak or short of breath, usually because of anemia, Pain or fullness below your ribs on the left side, due to an enlarged spleen, easy bruising and bleeding, night sweats, fever and bone pain. Pacritinib is an oral JAK inhibitor is the first treatment for adults with myelofibrosis and severe thrombocytopenia.

For a complete picture of PTSR and LoA scores for drugs in Thrombocythemia Myelofibrosis, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.